Latest News

Autolus Therapeutics recently reported its third quarter results, showing a reduction in net loss to US$79.12 million versus US$82.09 million a year ago, and announced operational advances including broad US market access for Obe-cel with 60 authorized treatment centers and a manufacturing success rate above 90%. The company is also progressing with clinical programs in pediatric ALL, lupus nephritis, and progressive multiple sclerosis, and announced leadership changes as it prepares for key...

Kyushu Financial Group (TSE:7180) has sparked renewed interest by executing a large share repurchase on the Tokyo Stock Exchange, in addition to raising its earnings guidance for the fiscal year ending March 2026. Both moves reflect a proactive approach to shareholder returns. See our latest analysis for Kyushu Financial Group. Kyushu Financial Group's sizable share repurchase and improved earnings outlook have certainly caught the market's attention, and that is apparent in the stock’s...

ABIVAX Société Anonyme (ENXTPA:ABVX) just shared patient-reported outcomes from its Phase 3 trial for obefazimod in adults with ulcerative colitis. These findings shed light on how patients actually experience the drug’s effects beyond clinical endpoints. See our latest analysis for ABIVAX Société Anonyme. After releasing the latest trial results and earning a spot in the Euronext 150 Index, ABIVAX Société Anonyme's stock has been on an impressive run. Momentum remains strong, with a 90-day...

PHINIA Inc.'s Audit Committee recently decided to engage Deloitte & Touche LLP as its independent registered public accounting firm for fiscal year 2026, replacing PricewaterhouseCoopers LLP after a competitive review, with the change approved on October 29, 2025. Switches in independent auditors can be closely watched as they may indicate changes in financial reporting or governance standards for a company. Given the incoming auditor transition, we’ll consider how this development could...

Hindustan Copper (NSE:HINDCOPPER) has had a great run on the share market with its stock up by a significant 40% over...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

In recent announcements, Nouveau Monde Graphite secured multiple binding supply agreements for nearly 100% of Phase-2 Matawinie Mine's future graphite production, including major contracts with Panasonic Energy and Traxys, while advancing project readiness for a final investment decision. These developments position NMG as a key supplier in both the battery and refractory sectors, underscoring its growing role in North American and European energy and manufacturing supply chains. We'll...

Rezolve AI recently announced the appointment of senior executives from leading technology firms, including Apple, Google, and Microsoft, to spearhead its expanded commercial rollout across the US and Europe, following a US$200 million oversubscribed financing and shelf registration closure of US$142.45 million. The influx of high-profile talent highlights industry confidence in Rezolve AI’s technology and signals an ambitious push into Agentic and Conversational Commerce markets. We'll...

Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...

Pirelli & C. S.p.A. recently announced earnings results for the nine months ended September 30, 2025, reporting sales of €5.20 billion and net income of €374.63 million, both up from the prior-year period. A key insight is that the company achieved higher basic earnings per share from continuing operations compared to last year, signaling a period of increased profitability. We’ll explore how Pirelli’s stronger earnings performance influences its investment narrative and the outlook for...

Zealand Pharma reported its third quarter 2025 results, announcing sales of DKK49.57 million and a quarterly net loss of DKK404.23 million, while nine-month sales reached DKK9.15 billion with net income of DKK6.83 billion. This rapidly shifting financial picture shows a swing from net loss to substantial net income over the nine-month period, underlining the impact of recent commercial developments. We'll now consider how Zealand's dramatic year-to-date earnings turnaround may influence the...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Food Empire Holdings fair value estimate is S$5.06 Food Empire...

Kaltura, Inc. recently reported its third-quarter 2025 results, showing revenue of US$43.87 million and a reduced net loss of US$2.63 million, alongside issuing updated guidance for the year and confirming no additional share repurchases in the recent quarter. A key insight from these announcements is the narrowing of Kaltura’s net loss year-over-year and modest nine-month revenue growth, suggesting some progress in controlling costs and supporting overall financial stability. We’ll examine...

Merus N.V. reported its third quarter 2025 earnings, showing revenue of US$12.15 million and a net loss of US$95.52 million, with the nine-month loss rising to US$350.21 million on revenue of US$47.47 million. While quarterly revenues edged up from last year, losses for the nine-month period grew dramatically as reported on October 31, 2025. We'll examine how Merus' ramp-up in nine-month revenues alongside widening losses shapes its current investment narrative. The end of cancer? These 29...

Simcere Pharmaceutical Group (SEHK:2096) has kicked off Phase II clinical trials in China for SIM0278, its IL-2 mutant fusion protein targeting moderate to severe atopic dermatitis. The new study highlights advances in selective immune therapies. See our latest analysis for Simcere Pharmaceutical Group. Momentum has been surging for Simcere Pharmaceutical Group lately, with the stock posting a 1-day share price return of 7.52% and an 18.01% gain over the past month. Its year-to-date share...

KSB SE & Co. KGaA announced increased sales revenue of €2.23 billion and order intake of €2.45 billion for the first nine months of 2025, while reaffirming its earnings guidance for the year. This combination of top-line growth and maintained guidance signals continued operational momentum despite broader economic uncertainties. We'll assess how this steady growth in sales and orders shapes KSB SE & Co. KGaA's investment narrative going forward. AI is about to change healthcare. These 31...

On November 11, 2025, Singapore Telecommunications announced strong half-year earnings with net income rising to S$3.40 billion and declared an interim ordinary dividend of 8.2 cents per share, comprising a core and value realisation portion. The notably higher net income and increased dividend payout highlight the company’s efforts to deliver tangible value to shareholders amid robust financial performance. We’ll explore how the combination of significant earnings growth and a boosted...

Following the solid earnings report from Rheinmetall AG ( ETR:RHM ), the market responded by bidding up the stock...

PEXA Group Limited ( ASX:PXA ) is possibly approaching a major achievement in its business, so we would like to shine...

You may think that with a price-to-sales (or "P/S") ratio of 8.7x Ventive Hospitality Limited ( NSE:VENTIVE ) is a...

Key Insights SK hynix's significant retail investors ownership suggests that the key decisions are influenced by...

In November 2025, European markets have been experiencing a pullback, with the pan-European STOXX Europe 600 Index declining by 1.24% amid concerns over artificial intelligence-related stock valuations. As investors navigate these fluctuating conditions, identifying stocks that may be trading below their fair value can present potential opportunities for those looking to capitalize on market inefficiencies and long-term growth prospects.

World Chess PLC's (LON:CHSS) stock price has dropped 31% in the previous week, but insiders who sold €1.2m in stock...